Global Study on Peptic Ulcer Drugs Market, 2016 - 2022
Global Study on Peptic Ulcer Drugs Market, 2016 - 2022 Persistence Market Research Global Peptic Ulcer Drugs Market to Reach US$ 40.0 Bn by 2022: Persistence Market Research Persistence Market Research 1 Global Study on Peptic Ulcer Drugs Market, 2016 - 2022 Persistence Market Research Released New Market Report According to a new market report published by Persistence Market Research ‘Global Market Study on Peptic Ulcer Drugs: North America to Lead in Global Market During Forecast Period 2016 - 2022, Driven by Increasing NSAID Consumption ’. According to this report, the global peptic ulcer drugs market will expand at CAGR of 2.8% during the forecast period 2016-2022. The market is segmented on the basis of product type, disease indication, distribution channel and region. By product type, the global peptic ulcer drugs market has been segmented into proton pump inhibitor (PPI), potassium-competitive acid blockers (P-CAB), antacids, H2-antagonists, antibiotics, and ulcer protective. Proton pump inhibitor segment was the largest revenue generating segment, contributing 69.1% share to the overall revenue of the global peptic ulcer drugs market in 2014. Revenue from the potassiumcompetitive acid blockers segment is expected to expand rapidly at a CAGR of 4.5% owing to introduction of new P-CAB drugs in the market. Based on indication, the global market for peptic ulcer drug is segmented as gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease. Gastric ulcer segment is anticipated to expand at highest CAGR of 3.0% over the forecast period. On the basis of distribution channels, the global peptic ulcer drugs market has been segmented as hospital pharmacies, private clinics, drug stores, retail pharmacies, and eCommerce. Among these, hospital pharmacies segment led the global market for peptic ulcer drugs in 2014 and is expected to remain the leading segment. Increasing hospitalization rates due to ulcer complications is expected to be the primary factor fuelling revenue growth of the hospital distribution channel segment over the forecast period. Geographically, peptic ulcer drugs market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Surge in consumption of NSAIDs due to growing prevalence of inflammatory diseases is the major factor driving growth of the global peptic ulcer drugs market. Other trends driving growth include increasing adoption of peptic ulcer drugs over surgery, changes in disease management, prevalence of stress ulcers due to higher smoking rates, availability of affordable therapy due to improvement in service sector, increasing awareness toward disease management through government campaigns etc. Chronic side effects associated Persistence Market Research 2 Global Study on Peptic Ulcer Drugs Market, 2016 - 2022 with long term use of peptic ulcer drugs is the major factor hampering the growth of global peptic ulcer drugs market. This report assesses trends driving each segment and offers analysis and insights about the potential of peptic ulcer drugs in specific regions. North America is expected to dominate the market, with a maximum share by the end of 2015. North America and Europe collectively accounted for 67% share of global peptic ulcer drugs market in 2014. Asia Pacific is estimated to be the fastest growing market, registering a CAGR of 3.5% during the forecast period. The report begins with overview of peptic ulcer drugs market in terms of value. This section covers optimistic, likely and conservative scenario in peptic ulcer drugs market. Overview of product launches in the peptic ulcer drugs market explains the evolution of treatment options over time. This report offers analysis of drivers, restraints, key trends in the region and global market, and potential opportunities to provide a client with clear insights to make better and informed decisions. Request Sample Report: http://www.persistencemarketresearch.com/samples/3704 Key players operating in this market are Daewoong Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca Plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Pharmaceuticals Ltd. These companies are primarily focusing on strategies such as co-promotions and co-marketing of their brands to penetrate the fastest growing emerging markets. View Detail Report With TOC: http://www.persistencemarketresearch.com/marketresearch/peptic-ulcer-drugs-market.asp Market History: Peptic ulcer refers to the group of gastrointestinal disorders including gastritis, gastric ulcers, and Duodenal ulcers or gastroesophageal reflux disease (GERD). Drugs used for the treatment of peptic ulcer include those which reduce gastric ulcer secretion such as PPI and H2 receptor antagonists, acid neutralization agents such as antacids and antibiotics against H. pylori infection. However, these drugs are often used in combination for effective Persistence Market Research 3 Global Study on Peptic Ulcer Drugs Market, 2016 - 2022 treatment. Depending upon the product type, peptic ulcer drugs market is segmented into proton pump inhibitors (PPIs), Potassium-Competitive Acid Blockers (P-CAB), antacids, H2 antagonists, antibiotics, and ulcer protective drugs. On the basis of indications, the market has been segmented into gastritis, gastric ulcers, duodenal ulcers, and gastroesophageal reflux disease (GERD). By distribution channel, the global peptic ulcer drugs market is segmented into hospital pharmacies, private clinics, drug stores, retail pharmacies, and eCommerce. The global peptic ulcer drugs treatment market was valued at US$ 32,200 Mn in 2014. North America led the global market 2014, accounting for 41.2% share of total global market revenue. The surge in use of non-steroidal anti-inflammatory drugs (NSAID) such as aspirin and growing awareness regarding treatment options for peptic ulcers are factors expected to drive the growth of the peptic ulcer drugs market in North America. The market in Europe accounted for a second largest share of 25.8%, primarily due to easy availability of successful treatment options for peptic ulcers in the region. Revenue from the global peptic ulcer drugs market is projected to expand at a steady CAGR of 2.8% over the forecast period and is expected to be valued at US$ 40,004.3 Mn by 2022 end. North America is expected to remain the dominant market, contributing 41.5% share to the global peptic ulcer drugs market in terms of revenue. The PPI and H2 antagonist product segments collectively accounted for 79.2% revenue share in 2014. The gastric ulcer indication segment was valued at US$ 5,279.8 Mn in 2014 and is expected to register the highest CAGR of 3.0% over the forecast period. Factors driving the growth of the global peptic ulcer drugs market include growing prevalence of peptic ulcers, increasing adoption of peptic ulcer drugs over surgery, R&D stimulation through government policies, increasing a number of generic manufacturers of peptic ulcer drugs, changes in disease management etc. Furthermore, factors such as growing prevalence of stress-induced ulcers due to changing lifestyle and diet, increasing smoking rate, and progressive population of geriatrics are anticipated to promote the growth of the global peptic ulcer drugs market over the forecast period. However, side effects of peptic ulcer drugs, poor pipeline productivity, and changes in pricing policies of drugs are factors expected to hamper the growth of the global peptic ulcer drugs market during this period. Persistence Market Research 4 Global Study on Peptic Ulcer Drugs Market, 2016 - 2022 Top players in the global peptic ulcer drugs market covered in this report are Daewoong Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Pfizer Inc., Abbott Laboratories, AstraZeneca plc., Cadila Healthcare Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Yuhan Corporation, and GlaxoSmithKline Plc. Follow us on Linkedin: https://www.linkedin.com/company/persistence-market-research-&consulting About Us: Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated research, custom research, and consulting services. PMR boasts market research expertise across the Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages, Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data that precisely corresponds to clients’ business needs. Contact Us: Persistence Market Research 5 Global Study on Peptic Ulcer Drugs Market, 2016 - 2022 Persistence Market Research 305 Broadway 7th Floor, New York City, NY 10007, United States, USA - Canada Toll Free: 800-961-0353 Email: [email protected] Web: http://www.persistencemarketresearch.com Persistence Market Research 6
© Copyright 2024